Joshua Liang, CEO
From inception, Clover has aimed to become a leading innovative biotechnology company delivering next-generation solutions to empower the global population with a healthier future. By leveraging our cutting-edge Trimer-Tag© technology and in-house manufacturing capabilities, we continue to discover, develop and deliver innovative and affordable medical solutions, with a mission to improve the quality of life and wellbeing of patients around the world.
Debilitating diseases such as cancer and viral infections remain difficult to treat or prevent. Moreover, public health threats such as the COVID-19 pandemic present new and complex challenges. Faced with significant unmet medical needs, Clover is utilizing its proprietary Trimer-Tag© technology to develop a robust portfolio of transformative biologics, and together with our in-house manufacturing capabilities, we are working diligently to make our biologics available, accessible and affordable for patients around the world as quickly as possible.
Over the past few years, the company has made great progress in several areas. We have expanded our cGMP biomanufacturing capacity, established a world-class global development team, established key cross-border collaborations and received more than $400 million in total capital since 2020.
At the early stages of the COVID-19 pandemic outbreak in 2020, Clover was among the first to initiate a COVID-19 vaccine program. Based on positive data from our Phase 1 clinical trial, the adjuvanted S-Trimer COVID-19 vaccine candidates are entering the final stage of clinical development – global Phase 2/3 clinical trials.
We are accelerating the development of our pipeline enabled by our Trimer-Tag© technology platform, including new vaccines and cancer therapies, several of which have entered the clinical stage. At the end of 2020, we have launched a new brand image, which unveils the next chapter for Clover. In this chapter, we will head towards a brighter future together with a more innovative, forward-looking and dynamic outlook.
Guided by Clover’s values – collaborative, loving, open, visionary, ethical and resilient – we will continue to transform scientific innovations into biologics that benefit people around the world.
Chief Executive Officer